Document is current
Any future updates will be listed below
-
Authors
Yang, Yu-ying
Deng, Yan-hua
Sun, Li-hao
Rejnmark, Lars
Wang, Ling
Pietschmann, Peter
Glüer, Claus‐Christian
A. Khan, Aliya
Minisola, Salvatore
Liu, Jian-min https://orcid.org/0000-0002-0179-1751
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 11 December 2024
First Online: 8 January 2025
Declarations
:
: Yu-ying Yang, Yan-hua Deng, Li-hao Sun, Ling Wang, Claus‐Christian Glüer and Jianmin Liu: no conflicts of interest.Lars Rejnmark: Investigator, had research funding and/or advisory board member for Takeda, Kyowa Kirin International, Ascendis, Amolyt and Calcilytix Therapeutics.Peter Pietschmann: received research support and/or honoraria from Amgen GmbH; Fresenius Kabi Austria GmbH, Meda Pharma/Mylan GmbH, Shire Austria GmbH/Takeda, TAmiRNA, UCB Pharma.Aliya A. Khan: had research funds from Amolyt, Takeda, and Ascendis.Salvatore Minisola: served as speaker for Abiogen, Beijing Society Biomedical Engineering, Bruno Farmaceutici, Diasorin, Geopharma, Sandoz, UCB; also served in advisory board of Abiogen, Ely Lilli, Kyowa Kirin, Faes Farma., Novo Nordisk, UCB.
